WHO ICTRP trial
Microwave ablation combined with tirelizumab and fuquinitinib in the treatment…
ChiCTR2200058323 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200058323 |
|---|---|
| Public title | Microwave ablation combined with tirelizumab and fuquinitinib in the treatment of third-line and posterior advanced colorectal cancer patients: a single-arm, open, single-center clinical study |
| Scientific title | Microwave ablation combined with tirelizumab and fuquinitinib in the treatment of third-line and posterior advanced colorectal cancer patients: a single-arm, open, single-center clinical study |
| Primary sponsor | Zhongshan Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | colorectal cancer |
| Interventions | Experimental group:Microwave ablation combined with tirelizumab and fuquintinib |
| Registration date | Apr 6, 2022 |
| Target size | Experimental group:25 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: